Sun Pharmaceutical Industries Ltd

Stage 3 · Topping · week 2

As of 9 Oct 2026, Sun Pharmaceutical Industries is in Stage 3 — topping, where an uptrend loses steam, in week 2 (since 29 Sep 2026). It closed at ₹1,760, 12.0% below its 52-week high and below its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, th… More about the company

₹1,760
+0.01% today
₹4.22L Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is SUNPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-12.0%
₹1,579 lo₹2,001.1 hi
12.0% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 2
1w13w26w
Week 2 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-2.5%
200 DMA: ₹1,805.9 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.77x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -2.9% vs MA50 -2.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-6.7%
3M
-9.1%
6M
+2.6%
YTD
+0.9%
1Y
+8.3%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
Sector has 74 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 16w
S2 28w
S2 19w
S3 15w
S4 19w
S2 28w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 16w → S3 1w → S2 28w → S3 8w → S2 19w → S3 15w → S4 8w → S1 6w → S4 19w → S1 4w → S2 9w → S3 7w → S2 28w → S3 2w current
Total tracked: 169 weeks across 14 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-03-18
3 appearances in last 60 days. First seen: 2024-07-22.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S3
Wk 2 · Vol 0.77x
2026-10-08S3
Wk 2 · Vol 0.88x
2026-10-07S3
Wk 2 · Vol 0.61x
2026-10-06S3
Wk 1 · Vol 0.78x
2026-10-05S3
Wk 1 · Vol 0.67x
2026-10-01S3
Wk 1 · Vol 1.22x
2026-09-30S3
Wk 1 · Vol 1.27x
2026-09-29S32→3
Wk 1 · Vol 1.66x
2026-09-28S2
Wk 28 · Vol 0.50x
2026-09-25S2
Wk 27 · Vol 0.36x
2026-09-24S2
Wk 27 · Vol 0.91x
2026-09-23S2
Wk 27 · Vol 0.46x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,887.4
200 DMA
₹1,805.9
52W High
₹2,001.1
52W Low
₹1,579
5D Low
₹1,759.8
Resistance levels (recent highs)
20d High
₹1,875
60d High
₹2,001.1
120d High
₹2,001.1
250d High
₹2,001.1
Next resistance
+6.5%
to 20d High
Ask the Market AI about SUNPHARMAAsk →
P/E (TTM)
38.5
Forward 28.5
Earnings Growth (YoY)
+25.6%
Revenue +12.8%
ROE
+14.7%
Profit margin +19.6%
Dividend Yield
0.90%
P/B 5.7
About this companyHealth Care· Pharmaceuticals

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.